Background: Concomitant hepatitis C virus infection (HCV) needs caution when selecting systemic treatments in psoriasis patients as some agents confer a risk of liver toxicity and/or are immunosuppressant. Phototherapy may provide a therapeutic choice but it is not always a practical option. Limited evidence supports the use of cyclosporine or TNF-α blockers. No data are available concerning the safety of efalizumab in patients with HCV infection. Objective: To describe the clinical characteristics and evolution of 5 adult patients with severe chronic plaque psoriasis and concomitant HCV infection who were treated with efalizumab. Method: A retrospective clinical case report. Results: Five adult patients with severe chronic plaque psoriasis and concomitant HCV infection were treated successfully using efalizumab with no increased viral replication and progression of liver disease for a follow-up of 8–20 months. Conclusion: Although further confirmation is needed, this report provides preliminary evidence to support also a cautious use of efalizumab in patients with HCV infection.

Keywords:
Psoriasis, Efalizumab, Hepatitis C virus infection
1.
Christophers E: Comorbidities in psoriasis. Clin Dermatol 2007;25:529–534.
2.
Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, Giannetti A, Girolomoni G: Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007;157:68–73.
3.
Girolomoni G, Gisondi P: Psoriasis and metabolic comorbidities: the importance of well-designed prospective studies. Dermatology 2008;217:222–224.
4.
Gottlieb AB, Chao C, Dann F: Psoriasis comorbidities. J Dermatol Treat 2008;19:5–21.
5.
Azfar RS, Gelfand JM: Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol 2008;20:416–422.
6.
Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, Korver G, Krueger GG, Strober BE, Lebwohl MG: National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008;58:1031–1042.
7.
Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ: The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705–714.
8.
Rantala M, van de Laar MJ: Surveillance and epidemiology of hepatitis B and C in Europe – a review. Euro Surveill 2008;13:18880.
9.
Ansaldi F, Bruzzone B, Salmaso S, Rota MC, Durando P, Gasparini R, Icardi G: Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. J Med Virol 2005;76:327–332.
10.
Taglione E, Vatteroni ML, Martini P, Galluzzo E, Lombardini F, Delle Sedie A, Bendinelli M, Pasero G, Bencivelli W, Riente L: Hepatitis C virus infection: prevalence in psoriasis and psoriatic arthritis. J Rheumatol 1999;26:370–372.
11.
Chouela E, Abeldaño A, Panetta J, Ducard M, Neglia V, Sookoian S, Kina M, Castaño G, Vereytou F, Frider B: Hepatitis C virus antibody (anti-HCV): prevalence in psoriasis. Int J Dermatol 1996;35:797–799.
12.
Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R: Guidelines of care for the management of psoriasis and psoriatic arthritis. 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826–850.
13.
Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels HM, Orzechowski HD, Prinz J, Reich K, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B: Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges 2007;5(suppl 3):1–119.
14.
Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler D, Finlay AY, Griffiths CE, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD: British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005;153:486–497.
15.
Krueger JG, Ochs HD, Patel P, Gilkerson E, Guttman-Yassky E, Dummer W: Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study. J Invest Dermatol 2008;128:2615–2624.
16.
Leonardi C, Menter A, Hamilton T, Caro I, Xing B, Gottlieb AB: Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol 2008;158:1107–1116.
17.
Gisondi P, Girolomoni G: Biologic therapies in psoriasis: a new therapeutic approach. Autoimmun Rev 2007;6:515–519.
18.
Nathan DM, Angus PW, Gibson PR: Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol 2006;21:1366–1371.
19.
NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consensus and State-of-the-Science Statements 2002;19:3. http://consensus.nih.gov/about/process.htm.
20.
Bravo AA, Sheth SG, Chopra S: Liver biopsy. N Engl J Med 2001;344:495–500.
21.
Vento S, Cainelli F, Longhi MS: Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 2002;3:333–340.
22.
Georgetson MJ, Yarze JC, Lalos AT, Webster GF, Martin P: Exacerbation of psoriasis due to interferon-alpha treatment of chronic active hepatitis. Am J Gastroenterol 1993;88:1756–1758.
23.
Nakagawa M, Sakamoto N, Tanabe Y, Koyama T, Itsui Y, Takeda Y, Chen CH, Kakinuma S, Oooka S, Maekawa S, Enomoto N, Watanabe M: Suppression of hepatitis C virus replication by cyclosporin A is mediated by blockade of cyclophilins. Gastroenterology 2005;129:1031–1041.
24.
Galeazzi M, Bellisai F, Giannitti C, Manganelli S, Morozzi G, Sebastiani GD: Safety of cyclosporin A in HCV-infected patients: experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection. Ann NY Acad Sci 2007;1110:544–549.
25.
Galeazzi M, Giannitti C, Manganelli S, Benucci M, Scarpato S, Bazzani C: Treatment of rheumatic diseases in patients with HCV and HIV infection. Autoimmun Rev 2008;8:100–103.
26.
Kallinowski B, Haseroth K, Marinos G, Hanck C, Stremmel W, Theilmann L, Singer MV, Rossol S: Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection. Clin Exp Immunol 1998;111:269–277.
27.
Farinati F, Cardin R, De Maria N, Della Libera G, Marafin C, Lecis E, Burra P, Floreani A, Cecchetto A, Naccarato R: Iron storage, lipid peroxidation and glutathion turnover in chronic anti-HCV positive hepatitis. J Hepatol 1995;22:449–456.
28.
Zein NN: Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005;42:315–322.
29.
Ferri C, Ferraccioli G, Ferrari D, Galeazzi M, Lapadula G, Montecucco C, Triolo G, Valentini G, Valesini G: Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 2008;35:1944–1949.
30.
Piccolo D, Cesare AD, Fargnoli MC, Paoloni M, Vecchiotti S, Peris K: Effective control of psoriasis by etanercept in a patient with HCV-related diseases. Eur J Dermatol 2008;18:459–460.
31.
Cecchi R, Bartoli L: Psoriasis and hepatitis C treated with anti-TNF alpha therapy (etanercept). Dermatol Online J 2006;12:4.
32.
Magliocco MA, Gottlieb AB: Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 2004;51:580–584.
33.
De Simone C, Paradisi A, Capizzi R, Carbone A, Siciliano M, Amerio PL: Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. J Am Acad Dermatol 2006;54:1102–1104.
34.
Domm S, Cinatl J, Mrowietz U: The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 2008;159:1217–1228.
35.
Langley RG, Carey WP, Rafal ES, Tyring SK, Caro I, Wang X, Wetherill G, Gordon KB: Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. Clin Ther 2005;27:1317–1328.
36.
Balato A, Balato N, Patruno C, Gallo L, Ayala F: Visceral leishmaniasis infection in a patient with psoriasis treated with efalizumab. Dermatology 2008;217:360–361.
37.
Weisenseel P, Kuznetsov AV, Flaig M, Prinz JC: Disseminated eruptive giant mollusca contagiosa in an adult psoriasis patient during efalizumab therapy. Dermatology 2008;217:85–86.
38.
Caudron A, Lok C, Clabaut A, Desblache J, Heyman B, Viseux V: Cytomegalovirus colitis in a patient treated with efalizumab. Dermatology 2009;218:84–85.
39.
Livio F, Ivanyuk A, Biollaz J: Pharmacovigilance and teratogen 2008. Rev Med Suisse 2009;5:130–134.
40.
http://www.emea.europa.eu/humandocs/PDFs/EPAR/raptiva/2085709en.pdf.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.